ReviewAntibiotics (Basel, Switzerland)2020
Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens.
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 144 citations in OpenAlex.
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
- Antibiotic-Free Strategies for Managing Antimicrobial-Resistant Infections.Pharmaceutics · 2026Review
- Human antibodies as emerging drugs for antimicrobial resistance.Trends in immunology · 2026Review
- Understanding hemolysin: from bacterial toxin to emerging treatments.Archives of microbiology · 2026Review
- Identification of multiple Acinetobacter baumannii protein antigens as targets for potential immunotherapies using a novel protein microarray screening approach.PLoS pathogens · 2026Article
- Coexist or eliminate? Antibody-based functional silencing versus eradication in gut microbiome- targeted therapy.Frontiers in immunology · 2026Review
- C-reactive protein is a broad-spectrum capsule-binding receptor for hepatic capture of blood-borne bacteria.The EMBO journal · 2025Article
- Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections:Drug delivery · 2025Review
- Bacteriophage-based therapies in oral cancer: A new frontier in oncology.Cancer pathogenesis and therapy · 2025Review
- Phage receptor binding protein and Fc fragment fusion enhances phagocytosis of Y. enterocolitica.AMB Express · 2025Article
- The Central Importance of Vaccines to Mitigate the Threat of Antibiotic-Resistant Bacterial Pathogens.Vaccines · 2025Review
- Reconstructing the Antibiotic Pipeline: Natural Alternatives to Antibacterial Agents.Biomolecules · 2025Review
- Antibiotics re-booted-time to kick back against drug resistance.npj antimicrobials and resistance · 2025Review
- Recent advances in antibody optimization based on deep learning methods.Journal of Zhejiang University. Science. B · 2025Review
- Harnessing intracellular bacteria in bladder by intravesical delivery of antibiotics-loaded nanodiamonds to reduce the recurrence of urinary tract infection.Journal of nanobiotechnology · 2025Article
- Monoclonal antibodies targeting Candida disrupt biofilms and inhibit growth across global clinical isolates.iScience · 2025Article
- Antimicrobial Potential of Cannabinoids: A Scoping Review of the Past 5 Years.Microorganisms · 2025Review
- Targeting bacterial transcription factors for infection control: opportunities and challenges.Transcription · 2025Review
- Novel broadly reactive monoclonal antibody protects againstInfection and immunity · 2025Article
- Metal compounds as antimicrobial agents: 'smart' approaches for discovering new effective treatments.RSC advances · 2025Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the beginning of the 21st century, the frequency of antimicrobial resistance (AMR) has reached an apex, where even 4th and 5th generation antibiotics are becoming useless in clinical settings. In turn, patients are suffering from once-curable infections, with increases in morbidity and mortality. The root cause of many of these infections are the ESKAPEE pathogens (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.